A Gupta1, W Fujita, I Gomes, E Bobeck, L A Devi. 1. Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
BACKGROUND AND PURPOSE: Opioid receptor function is modulated by post-activation events such as receptor endocytosis, recycling and/or degradation. While it is generally understood that the peptide ligand gets co-endocytosed with the receptor, relatively few studies have investigated the role of the endocytosed peptide and peptide processing enzymes in regulating receptor function. In this study, we focused on endothelin-converting enzyme 2 (ECE2), a member of the neprilysin family of metallopeptidases that exhibits an acidic pH optimum, localizes to an intracellular compartment and selectively processes neuropeptides including opioid peptides in vitro, and examined its role in modulating μ receptor recycling and resensitization. EXPERIMENTAL APPROACH: The effect of ECE2 inhibition on hydrolysis of the endocytosed peptide was examined using thin-layer chromatography and on μ opioid receptor trafficking using either elisa or microscopy. The effect of ECE2 inhibition on receptor signalling was measured using a cAMP assay and, in vivo, on antinociception induced by intrathecally administered opioids by the tail-flick assay. KEY RESULTS: The highly selective ECE2 inhibitor, S136492, significantly impaired μ receptor recycling and signalling by only those ligands that are ECE2 substrates and this was seen both in heterologous cells and in cells endogenously co-expressing μ receptors with ECE2. We also found that ECE2 inhibition attenuated antinociception mediated only by opioid peptides that are ECE2 substrates. CONCLUSIONS AND IMPLICATIONS: These results suggest that ECE2, by selectively processing endogenous opioid peptides in the endocytic compartment, plays a role in modulating opioid receptor activity. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
BACKGROUND AND PURPOSE: Opioid receptor function is modulated by post-activation events such as receptor endocytosis, recycling and/or degradation. While it is generally understood that the peptide ligand gets co-endocytosed with the receptor, relatively few studies have investigated the role of the endocytosed peptide and peptide processing enzymes in regulating receptor function. In this study, we focused on endothelin-converting enzyme 2 (ECE2), a member of the neprilysin family of metallopeptidases that exhibits an acidic pH optimum, localizes to an intracellular compartment and selectively processes neuropeptides including opioid peptides in vitro, and examined its role in modulating μ receptor recycling and resensitization. EXPERIMENTAL APPROACH: The effect of ECE2 inhibition on hydrolysis of the endocytosed peptide was examined using thin-layer chromatography and on μ opioid receptor trafficking using either elisa or microscopy. The effect of ECE2 inhibition on receptor signalling was measured using a cAMP assay and, in vivo, on antinociception induced by intrathecally administered opioids by the tail-flick assay. KEY RESULTS: The highly selective ECE2 inhibitor, S136492, significantly impaired μ receptor recycling and signalling by only those ligands that are ECE2 substrates and this was seen both in heterologous cells and in cells endogenously co-expressing μ receptors with ECE2. We also found that ECE2 inhibition attenuated antinociception mediated only by opioid peptides that are ECE2 substrates. CONCLUSIONS AND IMPLICATIONS: These results suggest that ECE2, by selectively processing endogenous opioid peptides in the endocytic compartment, plays a role in modulating opioid receptor activity. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
Authors: K Shirotani; S Tsubuki; N Iwata; Y Takaki; W Harigaya; K Maruyama; S Kiryu-Seo; H Kiyama; H Iwata; T Tomita; T Iwatsubo; T C Saido Journal: J Biol Chem Date: 2001-03-06 Impact factor: 5.157
Authors: H Yanagisawa; R E Hammer; J A Richardson; N Emoto; S C Williams; S i Takeda; D E Clouthier; M Yanagisawa Journal: J Clin Invest Date: 2000-05 Impact factor: 14.808
Authors: Achla Gupta; Ivone Gomes; Erin N Bobeck; Amanda K Fakira; Nicholas P Massaro; Indrajeet Sharma; Adrien Cavé; Heidi E Hamm; Joseph Parello; Lakshmi A Devi Journal: Proc Natl Acad Sci U S A Date: 2016-05-09 Impact factor: 11.205
Authors: Nestor Nivardo Jiménez-Vargas; Yang Yu; Dane D Jensen; Diana Daeun Bok; Matthew Wisdom; Rocco Latorre; Cintya Lopez; Josue O Jaramillo-Polanco; Claudius Degro; Mabel Guzman-Rodriguez; Quentin Tsang; Zachary Snow; Brian L Schmidt; David E Reed; Alan Edward Lomax; Kara Gross Margolis; Christoph Stein; Nigel W Bunnett; Stephen J Vanner Journal: Gut Date: 2021-03-30 Impact factor: 23.059
Authors: Dane D Jensen; Peishen Zhao; Nestor N Jimenez-Vargas; TinaMarie Lieu; Marina Gerges; Holly R Yeatman; Meritxell Canals; Stephen J Vanner; Daniel P Poole; Nigel W Bunnett Journal: J Biol Chem Date: 2016-03-30 Impact factor: 5.157
Authors: Ivone Gomes; Erin N Bobeck; Elyssa B Margolis; Achla Gupta; Salvador Sierra; Amanda K Fakira; Wakako Fujita; Timo D Müller; Anne Müller; Matthias H Tschöp; Gunnar Kleinau; Lloyd D Fricker; Lakshmi A Devi Journal: Sci Signal Date: 2016-04-26 Impact factor: 8.192
Authors: Natalia N Nalivaeva; Nikolai D Belyaev; Caroline Kerridge; Anthony J Turner Journal: Front Aging Neurosci Date: 2014-09-17 Impact factor: 5.750